Department of Transplantation, Mayo Clinic Florida, FL 32224, USA.
Ann Hepatol. 2012 Sep-Oct;11(5):679-85.
Patients with end stage liver disease may become critically ill prior to LT requiring admission to the intensive care unit (ICU). The high acuity patients may be thought too ill to transplant; however, often LT is the only therapeutic option. Choosing the correct liver allograft for these patients is often difficult and it is imperative that the allograft work immediately. Donation after cardiac death (DCD) donors provide an important source of livers, however, DCD graft allocation remains a controversial topic, in critically ill patients. Between January 2003-December 2008, 1215 LTs were performed: 85 patients at the time of LT were in the ICU. Twelve patients received DCD grafts and 73 received donation after brain dead (DBD) grafts. After retransplant cases and multiorgan transplants were excluded, 8 recipients of DCD grafts and 42 recipients of DBD grafts were included in this study. Post-transplant outcomes of DCD and DBD liver grafts were compared. While there were differences in graft and survival between DCD and DBD groups at 4 month and 1 year time points, the differences did not reach statistical significance. The graft and patient survival rates were similar among the groups at 3-year time point. There is need for other large liver transplant programs to report their outcomes using liver grafts from DCD and DBD donors. We believe that the experience of the surgical, medical and critical care team is important for successfully using DCD grafts for critically ill patients.
终末期肝病患者在接受肝移植 (LT) 之前可能会因病情危急而住进重症监护病房 (ICU)。这些高急症患者可能被认为病情太重而无法进行移植;然而,LT 通常是唯一的治疗选择。为这些患者选择正确的肝移植物通常很困难,而且移植物必须立即开始工作。心脏死亡后捐献 (DCD) 供体为提供了重要的肝脏来源,但在危重病患者中,DCD 供体的分配仍然是一个有争议的话题。2003 年 1 月至 2008 年 12 月,共进行了 1215 例 LT:1215 例 LT 中有 85 例患者在 ICU。12 例患者接受了 DCD 移植物,73 例患者接受了脑死亡后 (DBD) 移植物。排除再次移植和多器官移植后,本研究纳入了 8 例 DCD 移植物受者和 42 例 DBD 移植物受者。比较了 DCD 和 DBD 肝移植物的移植后结局。虽然 DCD 和 DBD 组在 4 个月和 1 年时点的移植物和生存率存在差异,但差异无统计学意义。3 年时点时,各组的移植物和患者生存率相似。其他大型肝移植项目需要报告使用 DCD 和 DBD 供体的肝移植物的结果。我们认为,外科、内科和重症监护团队的经验对于成功使用 DCD 移植物治疗危重病患者非常重要。